Showing results (1-10 of 162) with videos related to
Sort By:
Pageof 17
Endocrine-Related Cancer|August 15, 2014
Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsyRengyun Liu, Mingzhao XingEndocrine-Related Cancer|January 7, 2016
TERT promoter mutations in thyroid cancerRengyun Liu, Mingzhao XingEndocrine-Related Cancer|November 23, 2016
A six-genotype genetic prognostic model for papillary thyroid cancerXiaopei Shen, Rengyun Liu, Mingzhao XingOncogene|March 29, 2019
Identification and characterization of two novel oncogenic mTOR mutationsAvaniyapuram Kannan Murugan, Rengyun Liu, Mingzhao XingNature Communications|February 10, 2018
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancerRengyun Liu, Tao Zhang, Guangwu Zhu, et al.The Journal of Clinical Endocrinology and Metabolism|January 12, 2016
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer CellsWeiwei Cheng, Rengyun Liu, Guangwu Zhu, et al.Journal of the National Cancer Institute|December 19, 2023
Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressivenessRengyun Liu, Guangwu Zhu, Jie Tan, et al.Proceedings of the National Academy of Sciences of the United States of America|June 21, 2020
TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles HeelJie Tan, Rengyun Liu, Guangwu Zhu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 4, 2019
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerJiajun Liu, Rengyun Liu, Xiaopei Shen, et al.The Journal of Clinical Endocrinology and Metabolism|May 23, 2019
Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years OldZeming Liu, Xiaopei Shen, Rengyun Liu, et al.Pageof 17